University of Southern California

Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting welcomed the introduction of the first US Food and Drug Administration-approved anti-amyloid antibody for early Alzheim

Who: Takeda/AcuraStem What: Takeda is licensing a preclinical ALS candidate, an antisense oligonucleotide intended to suppress TDP-43 aggregation by addressing the PIKFYVE target. Why: Privately

The last ongoing clinical trial of Eli Lilly and Company ’s anti-amyloid antibody solanezumab has finally concluded and it failed to prevent symptomatic Alzheimer’s disease, but the data did offer so

Doctors who treat patients with Alzheimer’s disease – even neurologists involved in clinical trials for Biogen, Inc. / Eisai Co., Ltd. ’s Aduhelm (aducanumab) – are unsure who actually should be trea